Mlp Saglik Hizmetleri As Class B · BIST:MPARK
Mlp Saglik Hizmetleri As Class B — MLP Care — 9M 2025 Earnings Presentation
19 slides from Mlp Saglik Hizmetleri As Class B's earnings presentation, Nov 6, 2025
Slide 1: MLPCARE 9M 2025 Presentation
MLPCARE 9M 2025 PRESENTATION N o v e m b e r 6 th, 2 0 2 5
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain certain forward-looking statements concerning MLP Care’s future performance and should be considered as good faith estimates made by the Company. These forward-looking statements reflect management expectations and are based upon currently ava
Slide 3: Muharrem Usta, Chairman & CEO
MUHARREM USTA CHAIRMAN & CEO
Slide 4: Q3 2025 Financials at a Glance
Q3 2025 Financials at a Glance • Revenue Revenue growth supported by domestic EBITDA TL 13,064m TL 3,986 m private medical insurance 0,2% Growth 14% Growth 9M 2025: 9M 2025: • EBITDA improvement was driven by a 7% Growth 11% Growth favorable change in the payer mix and ongoing efficiency initiatives
Slide 5: Expanding its Network in Türkiye
Expanding its Network in Türkiye Medical Park Tem Hospital İstinye University Liv Hospital Topkapı Location: Istanbul / Türkiye Location: Istanbul / Türkiye Opening Date: August 2025 Opening Date: September 2025 Key Statistics Key Statistics 35.0k sqm 60.0k sqm 157 Bed Capacity 300 Bed Capac
Slide 6: Burcu Öztürk, CFO
Slide 7: Revenue Is up by 7%
Revenue Is up by 7% Revenue (TLm) 6.7% 39,221 36,749 0.2% 13,039 13,064 Q3 2024 Q3 2025 9M 2024 9M 2025 Denotes growth of Revenue vs. the same period of the last year 7
Slide 8: Continued Improvement in Average Prices
Continued Improvement in Average Prices Outpatient Revenues (TLm) Inpatient Revenues (TLm) 15.0% 6.1% 12.0% 4.0% 3.1% 2.1% 673 1.776 458 351 17.869 17.081 16.846 16.846 17.196 14.847 9M 2024 Volume & Mix Price 9M 2025 9M 2024 Volume & Mix Price 9M 2025 Average Revenue Per Visit (ARPV) Average Revenu
Slide 9: EBITDA is up by 11%
EBITDA is up by 11% EBITDA (TLm)1 10.7% 10,455 9,448 14.1% 3,986 3,493 Q3 2024 Q3 2025 9M 2024 9M 2025 1 EBITDA and EBITDA margin calculated by deducting general administrative expenses from gross profit and adding depreciation and amortization expenses Denotes growth of EBITDA vs. the same period o
Slide 10: Prudent Cost Management
Prudent Cost Management Cost of Service and G&A Expenses as a % of Revenues Cost Saving Measures enables us to reach the favourable EBITDA Margin EBITDA Margin 25.7% 26.7% Material costs as a % of revenue decreased by 150bps driven by effective inventory management and change in patient mix 9.6%
Slide 11: Bottom Line Improves Excluding One-off
Bottom Line Improves Excluding One-off Net Profit (TLm) Net Profit (TLm) Equity Holders of the Parent (Excluding One-off) Equity Holders of the Parent 3.1% (24.4%) 3.763 5.387 3.651 4.075 (32.8%) (41.9%) 2.787 1.944 1.307 1.619 Q3 2024 Q3 2025 9M 2024 9M 2025 Q3 2024 Q3 2025 9M 2024 9M 2025 Denotes
Slide 12: Net Debt Ratio Improves
Net Debt Ratio Improves Leverage Net Debt Net Debt excl. IFRS 16 12,212 5,740 6,599 0.9x 0.5x 0.4x 895 0.1x 2024 9M 2025 2024 9M 2025 *All figures are presented in million Turkish Lira 12 Denotes Net Debt / EBITDA multiples
Slide 13: CapEx Focused on Future Expansion
CapEx Focused Leverage on Future Expansion Ratio Improves CapEx increased by TL 3.6 billion year-on-year in the first nine months of 2025, mainly driven by expansion investments to secure future growth million TL 9M 2025 9M 2024 Maintenance: Includes floor openings, Total CapEx 7,198 3,470 renov
Slide 14: Cash Flow
Cash Flow million TL 9M 2025 9M 2024 Change EBITDA 10,455 9,448 1,007 Operating Cash Flow decreased due Changes in working capital (2,305) 1,955 (4,260) to increased working capital requirements Tax paid (956) (730) (226) Other (2.263) (1.788) (474) CapEx increased due to new hospital openings O
Slide 15: Q&A
Q&A
Slide 16: Closing Remarks
Closing Remarks MUHARREM USTA CHAIRMAN & CEO
Slide 17: Historical Balance Sheet
Historical Balance Sheet Unaudited Audited TLm September 30, 2025 December 31, 2024 Cash and cash equivalents 7,846 3,421 Trade receivables 8,453 7,635 Inventory 1,005 1,259 Short term other assets 2,639 1,718 Current assets 19,943 14,033 Tangible and intangible fixed assets 25,556 21,270 Right of u
Slide 18: Historical P&L Statements
Historical P&L Statements Unaudited Unaudited Unaudited Unaudited Change (%) Change (%) TLm 9M 2025 9M 2024 Q3 2025 Q3 2024 Revenues 39,221 36,749 %6.7 13,064 13,039 %0.2 Cost of service (-) (28,275) (26,791) %5.5 (9,085) (9,134) (%0.5) Gross profit 10,946 9,957 %9.9 3,979 3,905 %1.9 General adminis
Slide 19: EBITDA Reconciliation
EBITDA Reconciliation Change Change TLm 9M 2025 9M 2024 (%) Q3 2025 Q3 2024 (%) Revenue 39,221 36,749 6.7% 13,064 13,039 0.2% Cost of service (28,275) (26,791) 5.5% (9,085) (9,134) (0.5%) Gross profit 10,946 9,957 9.9% 3,979 3,905 1.9% General administrative expenses (-) (3,404) (3,062) 11.2% (1,068